HER2 Testing and Herceptin
Links shared publicly online about this topic
Breast Cancer - HER2 Test Approved | ThirdAge
thirdage.com — “A new genetic test that helps breast cancer patients determine if they are good candidates for treatment with the drug Herceptin was approved Tuesday by the U.S. Food and Drug Administration.” View full resource at thirdage.com
Most Recently Shared on June 15, 2011 at 4:22 pm By:
Breast Cancer - HER2 Test Approved http://bit.ly/lgX2L0
Inform Dual ISH HER2 Test Approved for Breast Cancer - ONA
oncologynurseadvisor.com — “The FDA has approved Inform Dual ISH from Ventana Medical Systems, a genetic test to help determine if women with breast cancer are HER2-positive and therefore candidates to receive Herceptin (trastuzumab; Genentech), a HER2 inhibitor.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 14, 2011 at 9:32 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Inform Dual ISH HER2 Test Approved for Breast Cancer http://goo.gl/fb/GHqur
FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer
drugs.com — “Herceptin (trastuzumab) is used to treat HER2-overexpressing breast cancer and metastatic gastric cancer. Includes Herceptin side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 21, 2010 at 3:04 am By:
FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer - http://bit.ly/bPZHjj
Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer
news-medical.net — “Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher who led what is regarded to be a key clinical trial determining the best use of Herceptin.” View full resource at news-medical.net
Most Recently Shared on December 14, 2009 at 6:52 am By:
Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer: Using Herceptin wi... http://bit.ly/54BdFr
Herceptin approved for HER2-positive metastatic stomach cancer - MPR
empr.com — “Genentech announced that Herceptin (trastuzumab) has been approved in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic cancer of the stomach or gastroesophageal junction, in patients who have not received prior medicines for their metastatic disease.” View full resource at empr.com
Most Recently Shared on October 21, 2010 at 3:10 pm By:
MPR News: Herceptin approved for HER2-positive metastatic stomach cancer: Genentech announced that Herceptin (tras... http://bit.ly/cHeChY
Herceptin approved for HER2-positive metastatic stomach cancer - ONA
oncologynurseadvisor.com — “Genentech announced that Herceptin (trastuzumab) has been approved in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic cancer of the stomach or gastroesophageal junction, in patients who have not received prior medicines for their metastatic disease.” View full resource at oncologynurseadvisor.com
Most Recently Shared on October 21, 2010 at 3:17 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Herceptin approved for HER2-positive metastatic stomach cancer http://goo.gl/fb/7pcEm
Herceptin Now Shown To Significantly Prolong The Lives Of Patients With HER2-positive Advanced Stomach Cancer
medicalnewstoday.com — “Roche announced results from a major international study which show that adding Herceptin (trastuzumab) to standard chemotherapy significantly prolongs lives of patients with HER2-positive stomach” View full resource at medicalnewstoday.com
Most Recently Shared on March 19, 2009 at 9:18 pm By:
John L LeRoy Jr MD Surgeon, Plastic Surgeon, Physician, and Doctor
http://bit.ly/t8vN Herceptin Now Shown To Significantly Prolong The Lives Of Patients With HER2-positive Advanced Stomach Cancer
Adding Multimedia FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer
medicalnewstoday.com — “Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced the U.S. Food and Drug Administration (FDA) has approved Herceptin® (trastuzumab) in combination with chemotherap” View full resource at medicalnewstoday.com
Most Recently Shared on October 22, 2010 at 2:05 pm By:
MNT Gastrointestinal Health News
Adding Multimedia FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer http://mnt.to/3Lzq #gastrointestinal
How exactly does Herceptin work?
healthtap.com — “Herceptin is a "monoclonal antibody". It is a protein that binds to receptors on breast cancer cells called HER-2. HER-2 causes breast cancer cells to grow uncontrollably. When Herceptin binds to these cells, it slows their growth. However, not all breast cancer cells contain the HER-2 receptors. Patients must be tested for the presence of HER-2 receptors before they are started on Herceptin.” View full resource at healthtap.com
Most Recently Shared on September 3, 2011 at 6:31 pm By:
Michael A. Zadeh, M.D. Physician, Doctor, and Surgeon
#HealthTap: How exactly does Herceptin work? Answer http://t.co/rzEetUn
Genentech Submits Supplemental Application To FDA For Herceptin In Advanced HER2-Positive Stomach Cancer
medicalnewstoday.com — “Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. F” View full resource at medicalnewstoday.com
Most Recently Shared on April 24, 2010 at 1:30 am By:
Genentech Submits Supplemental Application To FDA For Herceptin In Advanced HER2-Positive Stomach Cancer http://mnt.to/3BHj #cancer
Roche - Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer
www-origin2.roche.com — “Roche - Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer” View full resource at www-origin2.roche.com
Most Recently Shared on September 24, 2009 at 12:47 pm By:
eyeonfda Pharma and Health Lawyer
Roche - Herceptin demonstrates survival benefit for patients with high levels of HER2 in their stomach cancer http://bit.ly/GONkd
Roche - Herceptin proven to benefit women with HER2 positive early breast cancer - latest results from the HERA study
roche.com — “Roche - Herceptin proven to benefit women with HER2 positive early breast cancer - latest results from the HERA study” View full resource at roche.com
Most Recently Shared on March 11, 2009 at 6:51 am By:
Herceptin proven to benefit women with HER2 positive early breast cancer - latest results from the HERA study http://tinyurl.com/cpsvoq
Targeted agent addition to herceptin has positive effect on metastatic HER-2 breast cancer
medicalxpress.com — “Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the ...” View full resource at medicalxpress.com
Most Recently Shared on July 8, 2011 at 9:06 pm By:
PhysOrg Health News Health News
Targeted agent addition to herceptin has positive effect on metastatic HER-2 breast cancer http://tw.medicalxpress.com/229363588
Supplemental BLA submitted for Herceptin for advanced, HER2-positive adenocarcinoma of the stomach - ONA
oncologynurseadvisor.com — “Genentech announced that it submitted a supplemental Biologics License Application (sBLA) to the FDA for Herceptin (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.” View full resource at oncologynurseadvisor.com
Most Recently Shared on April 26, 2010 at 4:38 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Supplemental BLA submitted for Herceptin for advanced, HER2-positive adenocarcinoma of the… http://goo.gl/fb/iyq1S
Phase 2 study of Herceptin SC (subcutaneous) for the treatment of HER2-positive breast cancer - ONA
oncologynurseadvisor.com — “Halozyme Therapeutics announced that patient enrollment has been completed for a Phase 3 study of Herceptin SC (trastuzumab subcutaneous) for the treatment of HER2-positive breast cancer.” View full resource at oncologynurseadvisor.com
Most Recently Shared on December 15, 2010 at 7:56 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 2 study of Herceptin SC (subcutaneous) for the treatment of HER2-positive breast cancer http://goo.gl/fb/jvHLY
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
ThirdAge.com
A boomer's guide to a life of health, happiness, passion & purpose.
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
Advertisement
